Bemethyl (Bemitil) Research Standard
Bemethyl, also indexed as bemitil (CAS 14610-11-8), is 2-(ethylthio)benzimidazole — a 2-thio-substituted benzimidazole. It is supplied as the free base, and as a reference standard for laboratory work on hypoxia tolerance, tissue antioxidant biochemistry and xenobiotic metabolism. In the Soviet-era pharmacological literature it is the reference compound for the “actoprotector” class, a grouping defined by raising tolerance to physical load without a corresponding rise in oxygen consumption or heat production.[2] Researchers use it chiefly as a probe for effects that depend on induced protein synthesis rather than on direct receptor occupancy.
Mechanism of Action & Research Context
Note on salt form. This material is the free base (C9H10N2S, 178.26 g/mol). Much of the published literature works with bemethyl hydrobromide, which carries a different formula weight. Convert on a molar basis rather than by mass when reproducing a published concentration.
Bemethyl has no identified receptor target. There is no published binding panel, no Ki or IC50 dataset, and no ChEMBL record. What the literature does establish is a set of downstream biochemical effects and the fact that they require transcription and translation to occur.
-
The effect depends on de novo protein synthesis. In rats under acute hypobaric hypoxia, bemethyl preserved liver reduced glutathione, SH groups, glutathione reductase and glutathione peroxidase activity. Co-treatment with actinomycin D abolished the effect. This inhibitor result is the primary experimental support for a transcription-dependent mechanism, and it is the strongest mechanistic evidence in the compound’s file.[3]
-
The antioxidant action is indirect. In rat brain homogenate and isolated mitochondrial suspensions, bemitil limited malondialdehyde accumulation and organelle degradation, yet showed no antiradical activity of its own. The protection is therefore attributable to induced enzyme activity, not to the parent molecule scavenging radicals.[5]
-
Extensive phase II metabolism. LC-MS/HRMS of 24-hour rat urine identified nine metabolites across six molecular formulas, with a benzimidazole-acetylcysteine (mercapturate) conjugate the most abundant. Molecular docking to glutathione S-transferase supports a glutathione-conjugation route.[1]
-
Ion-channel effects occur only at very high concentrations. On isolated Lymnaea stagnalis neurons, bemethyl produced reversible, dose-dependent, non-selective block of slow sodium, calcium and potassium currents between 100 µM and 1 mM, with complete block at 10 mM. This is the one direct electrophysiology dataset available, and the concentrations involved place it well outside the range at which the compound’s other effects appear.[4]
-
Interaction with hypoxic adaptation. Bemethyl at 25 mg/kg i.p. over three days potentiated the adaptive metabolic and antioxidant changes produced in rat brain by intermittent hypoxic training.[6]
What is not established. The frequently repeated claims that bemethyl upregulates gluconeogenic enzymes, improves the coupling of oxidation and phosphorylation, or acts by mimicking purine bases to activate the genome are presented in the source review as suppositions, and that review states plainly that the concrete mechanisms remain unknown.[2] No retrieved primary study measures a gluconeogenic enzyme or a respiratory coupling ratio under bemethyl. Monoaminergic effects have been recorded in brainstem preparations without any target being identified. These should be treated as open questions.
Research Applications
Primary fields of laboratory investigation include:
-
Hypoxia tolerance models. Hypobaric and normobaric pressure-chamber protocols, and intermittent hypoxic training paradigms.[3,6]
-
Tissue antioxidant biochemistry. Glutathione, glutathione reductase and peroxidase activity, malondialdehyde and diene conjugate quantification in liver and brain.[3,5]
-
Transcription-dependence testing. Actinomycin D and related inhibitor designs to separate induced-protein effects from direct molecular action.[3]
-
Metabolite identification. LC-MS/HRMS profiling with in silico biotransformation prediction and enzyme docking.[1]
-
Electrophysiology. Voltage-clamp characterisation in isolated neuron preparations.[4]
Analytical Documentation
Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.
References
- Belinskaia DA, Savelieva EI, Karakashev GV, et al. Investigation of bemethyl biotransformation pathways by combination of LC-MS/HRMS and in silico methods. Int J Mol Sci. 2021;22(16):9021. doi:10.3390/ijms22169021
- Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446–456. doi:10.4062/biomolther.2012.20.5.446
- Zarubina IV, Mironova OP. Effect of bemethyl on the glutathione system in the rat liver in acute hypoxia. Eksp Klin Farmakol. 2002;65(3):28–30. PMID: 12227091.
- Vislobokov AI, Marysheva VV, Shabanov PD. Membrane mechanisms of effects of antihypoxic agents bemethyl and almide on neurons of Mollusca. Eksp Klin Farmakol. 2003;66(6):9–11. PMID: 14743702.
- Plotnikov MB, Saratikov AS, Plotnikova TM, et al. Antihypoxic and antioxidative properties of bemitil. Biull Eksp Biol Med. 1989;107(5):583–585. PMID: 2736293.
- Zarubina IV, Nurmanbetova FN, Shabanov PD. Bemithyl potentiates the antioxidant effect of intermittent hypoxic training. Bull Exp Biol Med. 2005;140(2):190–193. doi:10.1007/s10517-005-0442-8
Storage & Handling
Store at controlled room temperature. Keep tightly closed.
Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.
